News and press releases

Coloplast delivered 8% organic growth in the second quarter. Year to date organic growth was also 8% and reported revenue in Danish kroner was up by 9% to DKK 8,722m. This is mainly due to a positive development in USD against DKK, and currency developments increased revenue by 1% in the second quarter.

In the second quarter, the organic growth rates by business area were 6% in Ostomy Care, 9% in Continence Care, 10% in Interventional Urology, and 9% in Wound & Skin Care.

Looking at sales by geography in the second quarter, the European markets contributed with 6% growth, Other developed markets delivered 10% revenue growth, while Emerging Markets provided a 11% increase.

“We maintain solid growth rates across all geographical regions and business areas, and our organic revenue growth continues to be twice the market growth. I would like to highlight our strong performance in Europe driven by our product launches within Ostomy Care and Continence Care, SenSura® Mio Convex, SenSura® Mio Concave and SpeediCath® Flex, as well as our strong Wound Care performance driven by the Biatain® Silicone portfolio in Europe, particularly in the UK and France,” says CEO Kristian Villumsen, Coloplast. 

The incremental investments into innovation and sales and marketing initiatives of up to 2% of revenue that were initiated in Q1 are progressing according to plan.

EBIT amounted to DKK 2,639m for the first six months, a 10% increase in DKK, corresponding to an EBIT margin of 30% on par with the same period last year.


Important win in the US
Coloplast is the new primary ostomy supplier for Kindred at Home, a home health agency with more than 700 locations throughout 41 states. With an estimated market share of ~5%, Kindred at Home is the largest home health agency in the US.    

“The US market holds great potential for our company, and our ambition is to continue to take market share. Our aim is to deliver double digit growth in both Ostomy Care and Continence Care, while raising the standard of care and making sure patients have access to their preferred products. The contract with Kindred at Home is an important win for us,” says Mr Villumsen.

Financial guidance for 2018/19
Coloplast continues to expect organic revenue growth of ~8% at constant exchange rates and now a reported growth in DKK of ~9% from previously 8-9%.

Coloplast continues to expect an EBIT margin of 30%-31% at constant exchange rates and a reported EBIT margin of ~31% in DKK.

Capital expenditure is now expected to be DKK ~700m from previously DKK ~750m, and we continue to expect the effective tax rate to be ~23%.

As a result, FDA regulations require that all anterior transvaginal synthetic mesh products, including Coloplast’s Restorelle DirectFix Anterior device, can no longer be commercialized in the U.S., effective immediately. Coloplast will work with the FDA and other relevant authorities to ensure the orderly removal of these devices from customer inventories.

In accordance with the FDA guidance, Coloplast recommends that women who have received transvaginal mesh for the surgical repair of pelvic organ prolapse should continue with their annual and other routine check-ups and follow-up care. There is no need to take additional action if you are satisfied with your surgery and are not having any complications or symptoms. However, any patient with questions or concerns should speak to her healthcare provider. Please refer to the full statement on the  FDA website.

Coloplast is disappointed by the FDA decision to remove surgical transvaginal mesh as a treatment option for women suffering from pelvic organ prolapse. Coloplast has been committed to working with the FDA on the 522 clinical studies to document the long-term efficacy and safety of the products.

“Our mission at Coloplast is making life easier for people with intimate healthcare needs. Pelvic organ prolapses (POP) can be a painful, embarrassing, and a debilitating issue for the women who suffer from it. While mesh sales to treat POP in women account for approximately 0.2% of our global revenue, we firmly believe that patients and their physicians should have a choice of therapies. We are disappointed with the FDA’s decision because it reduces the treatment options for women with POP. We remain committed to providing alternative therapies.” says CEO Kristian Villumsen, Coloplast.

Coloplast has alternative solutions for the same type of products including tissue products as well as alternative procedures for pelvic organ prolapse. The FDA’s decision is limited to mesh for the transvaginal repair of pelvic organ prolapse and does not extend to mesh used to treat stress urinary incontinence.

Coloplast delivered 8% organic revenue growth in the first three months of the 2018/19 financial year, while reported growth in Danish kroner was up by 9% to DKK 4,321m. Currency developments reduced revenue by less than 1%, and revenue from acquisitions contributed 1%.

Organic growth rates by business area were 8% in Ostomy Care, 8% in Continence Care, 9% in Interventional Urology, and 11% in Wound & Skin Care.

Looking at sales by geography, the European markets contributed with 6% growth, Other developed markets delivered 10% revenue growth, while Emerging Markets provided a 14% increase.

“We maintain solid growth rates across all geographical regions and business areas. I would like to highlight our strong performance in Europe driven by new product launches and our Wound Care business delivering 10% organic growth driven by the Biatain® Silicone portfolio in UK and France. Our organic revenue growth is twice the market growth, and we maintain our guidance for 2018/19. In short, we are off to a good start to the financial year,” says newly appointed Coloplast CEO Kristian Villumsen. 

Investments in further growth
Coloplast continued its incremental investments in growth of up to 2% of revenue during the first quarter. Investments were made in innovation as well as sales and marketing initiatives across multiple markets and business areas.

In addition, Coloplast is expanding its SpeediCath® portfolio with the launch of SpeediCath® Navi. SpeediCath® Navi is a hydrophilic catheter designed specifically for Emerging Markets and it will be launched during 2019 and 2020.    

-        “As part of our investments in Emerging Markets, we’re proud to be able to offer a product developed specifically for catheter users in this region. Our aim is to raise the standard of care and to accommodate markets with lower reimbursement.  I’m confident that SpeediCath® Navi will make a big difference to our users, while giving Coloplast a strong competitive edge,” says Mr Villumsen.

Financial guidance for 2018/19
Coloplast continues to expect organic revenue growth of ~8% at constant exchange rates and a reported growth in DKK of 8-9%.

Coloplast continues to expect an EBIT margin of 30%-31% at constant exchange rates and a reported EBIT margin of ~31% in DKK.